Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

RESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc.

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regu ...

The vaccine, manufactured by US pharmaceutical giant Moderna, was found to slash the risk of severe illness from respiratory ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets ...

Persistent “stigma” and ignorance is holding back the development of new drugs to treat psychiatric conditions such as depression, according to one of the world’s leading brain scientists.

Around half a million Brits are now thought to be using weight loss jabs, however concerns have been raised about those ...

Biocon has announced the launch of its GLP-1 peptide Liraglutide for diabetes and obesity in the United Kingdom (U.K.).

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 ...